PT  - JOURNAL ARTICLE
AU  - Chauhan, Lakshmi
AU  - Pattee, Jack
AU  - Ford, Joshay
AU  - Thomas, Chris
AU  - Lesteberg, Kelsey
AU  - Richards, Eric
AU  - Loi, Michele
AU  - Dumont, Larry
AU  - Annen, Kyle
AU  - Berg, Mary
AU  - Zirbes, Mercedes
AU  - Miller, Amanda
AU  - Jenkins, Timothy C.
AU  - Bennett, Tellen D.
AU  - Monkowski, Daniel
AU  - Boxer, Rebecca S.
AU  - Beckham, J. David
TI  - A Multi-center, Prospective, Observational-cohort controlled study of Clinical Outcomes following COVID-19 Convalescent plasma therapy in hospitalized COVID-19 patients
AID  - 10.1101/2021.06.14.21258910
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.06.14.21258910
4099  - http://medrxiv.org/content/early/2021/06/18/2021.06.14.21258910.short
4100  - http://medrxiv.org/content/early/2021/06/18/2021.06.14.21258910.full
AB  - Background The SARS-CoV2 pandemic has caused high inpatient mortality and morbidity throughout the world. COVID19 convalescent plasma has been utilized as a potential therapy for patients hospitalized with COVID19 pneumonia. This study evaluated the outcomes of hospitalized COVID19 patients treated with COVID19 convalescent plasma in a prospective, observational multicenter trial.Methods From April 2020 through August 2020, hospitalized COVID19 patients at 16 participating hospitals in Colorado were enrolled and treated with COVID19 convalescent plasma (CCP) and compared to hospitalized patients with COVID19 who were not treated with convalescent plasma. Plasma antibody levels were determined following the trial given that antibody tests were not approved at the initiation of the trial. CCP-treated and untreated COVID19 hospitalized patients were matched using propensity scores followed by analysis for length of hospitalization and inpatient mortality.Results 542 total hospitalized COVID19 patients were enrolled at 16 hospitals across the region. A total of 468 hospitalized COVID19 patients were entered into propensity score matching with 188 patients matched for analysis in the CCP-treatment and control arms. Fine-Gray models revealed increased length of hospital stay in CCP-treated patients and no change in inpatient mortality compared to controls. In subgroup analysis of CCP-treated patients within 7 days of admission, there was no difference in length of hospitalization and inpatient mortality.Conclusions These data show that treatment of hospitalized COVID19 patients with CCP did not significantly improve patient hospitalization length of stay or inpatient mortality.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04471051Funding StatementThis study was supported in part by grant provided through Colorado Clinical and Translational Sciences Institute (CTSA Grant UL1 TR002535) to JDB. The study was also supported by institutional funds from University of Colorado Anschutz Medical Campus, Department of Medicine to JDBAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Colorado Multiple Institutional Review Board approved (20-0990 and 20-0986) the trial prior to study opening (4/2020). FDA IND Approval 21426, sponsor JD Beckham. ClinicalTrials.gov #NCT04471051.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data related to the trial are available per University of Colorado data sharing and IRB guidelines.